CTIS2023-507454-33-00招募中1 期
ECS_IAMA23_0101
Iama Therapeutics S.r.l.0 个研究点目标入组 72 人开始时间: 2023年10月5日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A Phase 1b Study of Imvotamab in Severe Systemic Lupus ErythematosusSystemic Lupus ErythematosusCTIS2023-506499-29-00IGM Biosciences Inc.18
进行中（未招募）
1 期
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing ticagrelor 90 mg hard capsules (PG402 [Celon Pharma]) vs ticagrelor 90 mg film-coated tablets (Brilique [AstraZeneca AB]) under fasting conditions in healthy volunteersPrevention of atherothrombotic events in adult patients with- acute coronary syndromes (ACS) or- a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic eventMedDRA version: 20.0Level: PTClassification code: 10028596Term: Myocardial infarction Class: 100000004849CTIS2023-504116-14-00Celon Pharma S.A.40
进行中（未招募）
1 期
A study to characterize the safety, efficacy, pharmacokinetics of subcutaneous administration of ABBV-383 in patients with relapsed or refractory Multiple MyelomaCTIS2023-507901-32-00AbbVie Deutschland GmbH & Co. KG55
招募中
1 期
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid ArthritisMedDRA version: 21.0Level: PTClassification code: 10039073Term: Rheumatoid arthritis Class: 100000004859Rheumatoid ArthritisCTIS2023-505127-31-00IGM Biosciences Inc.24
进行中（未招募）
1 期
Bioequivalence study of the oral suspension of netupitant/palonosetron combination product versus the hard capsules of netupitant/palonosetron combination product after a single dose administration to healthy male and female volunteers in an open-label, randomised, single centre, 2-treatment, 4-period, 2 sequence replicative desigHealthy volunteersCTIS2023-504355-28-03Helsinn Healthcare S.A.74